EA202090533A3 - ANTIBODIES TO OX40 AND THEIR APPLICATION - Google Patents

ANTIBODIES TO OX40 AND THEIR APPLICATION

Info

Publication number
EA202090533A3
EA202090533A3 EA202090533A EA202090533A EA202090533A3 EA 202090533 A3 EA202090533 A3 EA 202090533A3 EA 202090533 A EA202090533 A EA 202090533A EA 202090533 A EA202090533 A EA 202090533A EA 202090533 A3 EA202090533 A3 EA 202090533A3
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
light chain
chain variable
variable region
polynucleotides encoding
Prior art date
Application number
EA202090533A
Other languages
Russian (ru)
Other versions
EA202090533A2 (en
Inventor
Чжэхун Цай
Индрани Чакраборти
Мари-Мишель Наварро Гарсиа
Томас Д. Кемпе
Алан Дж. Корман
Александр Т. Кожич
Хадиа Лемар
Марк МОРЕ
Кристина Мариа Милберн
Майкл Куигли
Мариа Родригес
Сян Шао
Мохан Сринивасан
Бренда Л. Стивенс
Кент Тудиум
Сусань Чиэнь-Цзу Вонг
Йохем Гокмайер
Си-Тао Ван
Хань Чан
Кристин Хуанг
Мария Джуре-Кункел
Чжэн Ян
Ян Фенг
Патрик Гуирналда
Нилс Лонберг
Брайан С. Барнхарт
Аарон П. Ямнюк
Карла А. Хеннинг
Мишель Миньхуа Хан
Мин Лей
Лианг Швайцер
Сандра В. Хэтчер
Арвинд РАДЖПАЛ
Правиин Аанур
Марк Дж. Селби
Original Assignee
Бристол-Майерс Сквибб Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Бристол-Майерс Сквибб Компани filed Critical Бристол-Майерс Сквибб Компани
Publication of EA202090533A2 publication Critical patent/EA202090533A2/en
Publication of EA202090533A3 publication Critical patent/EA202090533A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

В настоящем изобретении предусмотрены антитела или их антигенсвязывающие части, которые связываются с OX40. Также предусмотрено применение этих белков в терапевтических применениях, таких как лечение злокачественной опухоли. Дополнительно предусмотрены клетки, которые производят антитела, полинуклеотиды, кодирующие вариабельную область тяжелой и/или легкой цепи антител, и векторы, содержащие полинуклеотиды, кодирующие вариабельную область тяжелой и/или легкой цепи антител.The present invention provides antibodies or antigen-binding portions thereof that bind to OX40. Also contemplated is the use of these proteins in therapeutic applications such as the treatment of cancer. Additionally provided are cells that produce antibodies, polynucleotides encoding an antibody heavy and / or light chain variable region, and vectors containing polynucleotides encoding an antibody heavy and / or light chain variable region.

EA202090533A 2016-05-09 2016-05-26 ANTIBODIES TO OX40 AND THEIR APPLICATION EA202090533A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662333556P 2016-05-09 2016-05-09

Publications (2)

Publication Number Publication Date
EA202090533A2 EA202090533A2 (en) 2020-07-31
EA202090533A3 true EA202090533A3 (en) 2020-10-30

Family

ID=71833527

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202090533A EA202090533A3 (en) 2016-05-09 2016-05-26 ANTIBODIES TO OX40 AND THEIR APPLICATION

Country Status (1)

Country Link
EA (1) EA202090533A3 (en)

Also Published As

Publication number Publication date
EA202090533A2 (en) 2020-07-31

Similar Documents

Publication Publication Date Title
EA201792572A1 (en) ANTIBODIES TO OX40 AND THEIR APPLICATION
EA201891121A1 (en) ANTIBODIES TO THE GLUKORTIKOID-INDUCED RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
MY200602A (en) Antibodies against tim3 and uses thereof
EA201692459A1 (en) ANTIBODIES TO INDUCED GLUCOCORTICOIDS RECEPTOR OF THE TUMOR NECROSIS FACTOR (GITR) AND THEIR APPLICATIONS
CY1123977T1 (en) ANTI-PD-1 AND ANTI-LAG3 ANTIBODIES FOR THE TREATMENT OF CANCER
EA202090104A1 (en) ANTIBODY MOLECULES TO CD73 AND WAYS OF THEIR APPLICATION
EA201990346A1 (en) ANTIBODIES TO GPRC5D, BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND GPRC5D AND CD3, AND THEIR APPLICATION
EA201890145A1 (en) ANTIBODIES TO FACTOR XI AND METHODS OF THEIR APPLICATION
EA202092417A1 (en) CHIMERIC RECEPTORS TO DLL3 AND METHODS OF THEIR APPLICATION
EA202092306A1 (en) ANTI-CD24 COMPOSITIONS AND THEIR APPLICATIONS
EA201892294A1 (en) ANTIBODIES AND COMPOSITIONS AGAINST TIM-3
EA201891992A1 (en) CHIMERIC RECEPTORS AND WAYS OF THEIR APPLICATION
EA201890513A1 (en) ANTIBODIES TO BCMA, BISPECIFIC ANTIGENS-BINDING MOLECULES THAT ARE BINDING WITH BCMA AND CD3 AND THEIR APPLICATION
EA201792221A1 (en) ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION
EA201991720A1 (en) ANTIBODIES TO ALPHA-SINUCLEIN AND THEIR APPLICATIONS
EA201690443A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO CONNECT CD123 AND CD3 AND THEIR APPLICATIONS
EA202191380A1 (en) ANTIBODIES TO ALPHA-SYNUCLEINE AND THEIR APPLICATION
EA201891732A1 (en) BISPECIFIC BINDING PROTEINS FOR PD-L1 AND KDR
EA201790719A1 (en) BISPECIFIC MONOVALENT DIATELS, WHICH ARE CAPABLE TO BIND CD19 AND CD3, AND THEIR APPLICATION THEREOF
EA201992206A1 (en) MONOCLONAL ANTIBODY TO PD-L1
EA201892225A1 (en) ANTIBODIES TO THE COMPLEX Bb FACTOR AND THEIR APPLICATION
EA202190235A1 (en) ANTIBODIES TO CD33 AND METHODS OF THEIR APPLICATION
EA202090533A3 (en) ANTIBODIES TO OX40 AND THEIR APPLICATION
EA202090864A1 (en) MONOCLONAL ANTIBODY TO IL-5R
EA201990176A1 (en) ANTIBODIES TO TIM3 AND THEIR APPLICATION